PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26021F0040Treprostinil 0.6mg ML — United Therapeutics Corp

United Therapeutics Corp holds $3.8M across 190 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award in the incumbent pipeline.

260-Network Contract Office 20 (36C260)
Awarding office
United Therapeutics Corp
Recipient
—
Estimated value
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal
Contract number36C26021F0040
Also listed as36C260-21-F-0040
Agency260-Network Contract Office 20 (36C260)
Awarding office260-Network Contract Office 20 (36C260)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentUnited Therapeutics Corp
UEIKK5FBFA43JS7
PSC6505

TREPROSTINIL 0.6MG/ML is a federal award for 260-Network Contract Office 20 (36C260) held by United Therapeutics Corp. Estimated value —.

Bonuses end Sept 30

Want the durability read on 36C26021F0040? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

United Therapeutics Corp — $3.8M obligated across 190 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($3.8M) · all agencies
Department of Veterans Affairs (VA)$3.7M · 97%Department of Justice (DOJ)$118K · 3%
Open full company profile →

Related awards

Same incumbent
36C26026F0064
TYVASO KITS & CARTRIDGES
$379K
Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 36C26021F0040?

36C26021F0040 (Treprostinil 0.6mg ML) is a 260-Network Contract Office 20 (36C260) award with an estimated value of —, currently held by United Therapeutics Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-21-F-0040?

36C260-21-F-0040 is the dashed form of PIID 36C26021F0040 (Treprostinil 0.6mg ML), held by United Therapeutics Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26021F0040?

260-Network Contract Office 20 (36C260) awarded 36C26021F0040 to United Therapeutics Corp.

Who is the incumbent on 36C26021F0040?

United Therapeutics Corp is the incumbent with $3.8M across 190 related awards in SCOUT’s public footprint.

When does United Therapeutics Corp’s 36C26021F0040 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 36C26021F0040? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C26021F0040